IGM-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022